(Q37634504)

21 August 2017

1 reference

title

Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders (English)

1 reference

major depressive disorder

21 August 2017

main subject

1 reference

Julien Mendlewicz

1

1 reference

21 August 2017

publication date

1 January 2009

1 reference

World Journal of Biological Psychiatry

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

4

1 reference

21 August 2017

page(s)

269-275

1 reference

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Sleep EEG, depression and gender

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Microarchitectural findings in sleep EEG in depression: diagnostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

The effects of antidepressants on sleep in patients with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Symposium: Normal and abnormal REM sleep regulation: REM sleep in depression-an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Mirtazapine for the treatment of hot flushes in breast cancer survivors: a prospective pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Prodromal symptoms in primary major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

EEG sleep profiles and recurrent depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Delta sleep ratio. A biological correlate of early recurrence in unipolar affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Sleep Electroencephalography in Depressive Illness a Collaborative Study by the World Health Organization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Changes in forebrain function from waking to REM sleep in depression: preliminary analyses of [18F]FDG PET studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Size and burden of depressive disorders in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Place of chronic insomnia in the course of depressive and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Severe depression: is there a best approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Antidepressants and sleep: a qualitative review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

Novel naphthalenic ligands with high affinity for the melatonin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622970802503086

10.3109/15622970802503086

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference